NCT05139017 2026-04-20
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
Clinical Trials
5 trialsNCT04799275 2026-04-14
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
National Cancer Institute (NCI)
Phase 2/3 Suspended
NCT03984448 2026-04-13
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT02405676 2026-03-19
BNHL-2015
Children's Cancer Group, China
Phase 2/3 Active not recruiting
NCT05991388 2026-02-20
Glo-BNHL
University of Birmingham
Phase 2/3 Recruiting